Pharma — April 2023
-
Inovio Presents Data From Phase 1b Trial With INO-4201 As Ebola Booster For RVSV-ZEBOV https://www.proinvestor.com/investornyt/968741/inovio-presents-data-from-phase-1b-trial-with-ino-4201-as-ebola-booster-for-rvsv-zebov
-
Is Johnson & Johnson a Buy After Its Proposed $8.9 Billion Talc Settlement? https://www.proinvestor.com/investornyt/968764/is-johnson-amp-johnson-a-buy-after-its-proposed-89-billion-talc-settlement
-
Dråbesalg styrker ALK-Abelló på toplinje og drift i første kvartal https://www.proinvestor.com/investornyt/969131/drabesalg-styrker-alk-abello-pa-toplinje-og-drift-i-forste-kvartal
-
HC Wainwright & Co. Reiterates Axsome Therapeutics (AXSM) Buy Recommendationhttps://www.proinvestor.com/investornyt/969108/hc-wainwright-amp-co-reiterates-axsome-therapeutics-axsm-buy-recommendation
-
Wells Fargo Initiates Coverage of Viridian Therapeutics (VRDN) with Overweight Recommendation https://www.proinvestor.com/investornyt/969111/wells-fargo-initiates-coverage-of-viridian-therapeutics-vrdn-with-overweight-recommendation
-
Stimen af opkøb fortsætter: GSK To Buy BELLUS Health In US$2.0 Bln Deal https://www.proinvestor.com/investornyt/969145/gsk-to-buy-bellus-health-in-us20-bln-deal
-
Basilea Provides Updated Timeline For NDA Submission For Antibiotic Ceftobiprole To FDA https://www.proinvestor.com/investornyt/969136/basilea-provides-updated-timeline-for-nda-submission-for-antibiotic-ceftobiprole-to-fda
-
FDA Approves Omisirge Cell Therapy For
Blood Cancers https://www.proinvestor.com/investornyt/969139/fda-approves-omisirge-cell-therapy-for-blood-cancers -
Teva, Alvotech's Humira biosimilar hit with second FDA rejection
https://firstwordpharma.com/story/5727774 -
FDA panel backs approval of Rexulti for Alzheimer's-related agitation https://firstwordpharma.com/story/5728435
-
Pyramid Bio bets on GeneQuantum's ADC candidate for over $1 billion
https://firstwordpharma.com/story/5727433 -
Merck & XtalPi Collaboration Optimizes Drug Formulations with AI-Powered Techniques https://firstwordpharma.com/story/5727905
-
AbbVie's Rinvoq nabs EU approval in Crohn's disease https://firstwordpharma.com/story/5728428
-
Danske Bank skærer anfaling og kursmål for ALK: Tal svagere end ventet
https://www.proinvestor.com/investornyt/969155/danske-bank-skaerer-anfaling-og-kursmal-for-alk-tal-svagere-end-ventet -
Johnson & Johnson opjusterer forventningerne til 2023 https://www.proinvestor.com/investornyt/969240/johnson-johnson-opjusterer-forventningerne-til-2023
-
Norsk storbank mener nedjusteret prognose hos ALK skaber usikkerhed https://www.proinvestor.com/investornyt/969333/norsk-storbank-mener-nedjusteret-prognose-hos-alk-skaber-usikkerhed
-
ALK-Abelló/SEB: Kursmål sænkes til 130 kr. fra 140 kr. https://www.proinvestor.com/investornyt/969717/alk-abello-seb-kursmal-saenkes-til-130-kr-fra-140-kr
-
FDA Authorizes Changes To Simplify Use Of Moderna, Pfizer Bivalent COVID-19 Vaccines https://www.proinvestor.com/investornyt/969745/fda-authorizes-changes-to-simplify-use-of-moderna-pfizer-bivalent-covid-19-vaccines
-
Lundbeck når primære endepunkt i migræneforsøg i Hope-studie https://www.proinvestor.com/investornyt/970031/lundbeck-nar-primaere-endepunkt-i-migraeneforsog-i-hope-studie
-
Sydbank kalder Lundbecks migrænemiddel for spændende i stort migrænemarked
https://www.proinvestor.com/investornyt/970057/sydbank-kalder-lundbecks-migraenemiddel-for-spaendende-i-stort-migraenemarked
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind